HOME >> BIOLOGY >> NEWS
A novel mechanism of action for anti-tumor agent, CA4P

Anti-angiogenic agents have been successful in the clinic for blocking the growth of solid tumors. However, these agents used in combination with chemotherapy have improved the survival of patients with cancers by only several months. Therefore, identification of unrecognized angiogenic pathways that selectively support tumor neo-vessel assembly will increase the efficacy of anti-angiogenic or anti-vascular therapy.

The prototypical vascular targeting agent combretastatin A4 phosphate (CA4P) exerts its anti-angiogenic effect by targeting unstable budding tumor neo-vessels. CA4P is currently being studied in clinical trials in oncology.

In a paper appearing online on October 6 in advance of print publication of the November issue of the Journal of Clinical Investigation, Shahin Rafii and colleagues from Cornell University provide important mechanistic data demonstrating how CA4P has anti-tumor and anti-angiogenic activity.

The authors find that CA4P selectively targets endothelial cells (flat-shaped cells that make up the inside of blood vessels) but not smooth muscle cells (cells which surround most blood vessels), and induces regression of unstable, newly formed vessels by disruption of Vascular Endothelial-cadherin (VE-cadherin) signaling. VE-cadherin is a protein found at the junctions of overlapping regions of endothelial cells and plays a key role in many aspects of vascular function including, endothelial cell survival, cell migration, cell proliferation and assembly into vessel-like structures.

Dissecting the mechanism whereby CA4P exerts its anti-vascular effect will open up new avenues of research to selectively target tumor neo-vessels and increase the therapeutic window of anti-angiogenic agents.


'"/>

Contact: Stacie Bloom
press_releases@the-jci.org
212-342-4159
Journal of Clinical Investigation
6-Oct-2005


Page: 1

Related biology news :

1. CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell
2. UB scientist discovers novel iron-copper alliance
3. A novel molecular dictator with a conscience discovered
4. Researchers pit novel version of common virus against cancer
5. UCLA researchers discover novel pathway that may promote immune system balance
6. pHLIP, a novel technology to locate and treat tumors
7. Bioluminescence at the service of a novel cerebral imaging technique
8. Application of Genomatix in silico methods reveals novel cancer associated genes
9. Two studies: Speeding development of novel tracer for prostate cancer
10. Erythrocyte G protein as a novel target for malarial chemotherapy
11. U of MN researchers find novel genes critical in organ development

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... August 03, 2020 , ... ... new partnership with medical equipment manufacturer, Spectrum Solutions, to provide COVID-19 saliva testing ... their laboratory supply chain for more than 10 years. Early in the COVID-19 ...
(Date:7/18/2020)... ... 16, 2020 , ... A study has been published in ... active noise control device to attenuate typical noises in a simulated neonatal intensive ... alarm sounds from patient monitors, ventilators and other bedside devices that would affect ...
(Date:7/4/2020)... ... July 03, 2020 , ... Aesthetics Biomedical (ABM), a leading ... for not only the products and treatments developed, but also the dedicated team ... All the brands built by ABM have received several honors already for 2020, ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... ... 13, 2020 , ... True Terpenes , the leading platform for terpene ... (SAB) to research the medical potential of terpenes and the potential entourage effect ... The board is focused on expanding the recently launched line of effects-based terpenes - ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... chain validation engineering firm, is making available for free its new white ... incorporate concurrent transport simulation testing into today’s biologics licensing application (BLA). In ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... announced Jim Corrigan, President and CEO has been named one of the 100 ... of industry sectors, PharmaVoice 100 honorees are selected based on how they have ...
(Date:7/31/2020)... ... 29, 2020 , ... G-CON Manufacturing, the leader in off-site ... FOR LIFE.” The adoption of this taglines comes at a time of tremendous ... to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. G-CON’s ...
Breaking Biology Technology:
Cached News: